Capricor Therapeutics CAPR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockOptionPlanExpense.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's stock-based comp?
- Capricor Therapeutics (CAPR) reported stock-based comp of $5.92M in Q1 2026.
- How has Capricor Therapeutics's stock-based comp changed year-over-year?
- Capricor Therapeutics's stock-based comp increased by 8.0% year-over-year, from $5.48M to $5.92M.
- What is the long-term trend for Capricor Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Capricor Therapeutics's stock-based comp has grown at a 54.7% compound annual growth rate (CAGR), from $2.97M to $16.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.